A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors

Trial Profile

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 27 May 2016

At a glance

  • Drugs Panitumumab (Primary)
  • Indications CNS cancer; Glioma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Amgen
  • Most Recent Events

    • 07 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Aug 2014 New source identified and integrated (Vanderbilty - Ingram Cancer Center - VICCPED1395).
    • 06 Sep 2013 Planned end date changed from 1 Jul 2013 to 1 Jun 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top